JPWO2019189778A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019189778A5
JPWO2019189778A5 JP2020511101A JP2020511101A JPWO2019189778A5 JP WO2019189778 A5 JPWO2019189778 A5 JP WO2019189778A5 JP 2020511101 A JP2020511101 A JP 2020511101A JP 2020511101 A JP2020511101 A JP 2020511101A JP WO2019189778 A5 JPWO2019189778 A5 JP WO2019189778A5
Authority
JP
Japan
Prior art keywords
formula
group represented
pharmaceutically acceptable
acceptable salt
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511101A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019189778A1 (ja
JP7374887B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/014042 external-priority patent/WO2019189778A1/ja
Publication of JPWO2019189778A1 publication Critical patent/JPWO2019189778A1/ja
Publication of JPWO2019189778A5 publication Critical patent/JPWO2019189778A5/ja
Priority to JP2023182872A priority Critical patent/JP7631473B2/ja
Application granted granted Critical
Publication of JP7374887B2 publication Critical patent/JP7374887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511101A 2018-03-30 2019-03-29 抗がん活性を有する化合物 Active JP7374887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023182872A JP7631473B2 (ja) 2018-03-30 2023-10-24 抗がん活性を有する化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018068816 2018-03-30
JP2018068816 2018-03-30
PCT/JP2019/014042 WO2019189778A1 (ja) 2018-03-30 2019-03-29 抗がん活性を有する化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023182872A Division JP7631473B2 (ja) 2018-03-30 2023-10-24 抗がん活性を有する化合物

Publications (3)

Publication Number Publication Date
JPWO2019189778A1 JPWO2019189778A1 (ja) 2021-04-08
JPWO2019189778A5 true JPWO2019189778A5 (https=) 2022-04-06
JP7374887B2 JP7374887B2 (ja) 2023-11-07

Family

ID=68062014

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511101A Active JP7374887B2 (ja) 2018-03-30 2019-03-29 抗がん活性を有する化合物
JP2023182872A Active JP7631473B2 (ja) 2018-03-30 2023-10-24 抗がん活性を有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023182872A Active JP7631473B2 (ja) 2018-03-30 2023-10-24 抗がん活性を有する化合物

Country Status (21)

Country Link
US (3) US11629152B2 (https=)
EP (1) EP3778573B1 (https=)
JP (2) JP7374887B2 (https=)
KR (1) KR102765467B1 (https=)
CN (1) CN111936468B (https=)
AU (1) AU2019242518B2 (https=)
BR (1) BR112020019963A2 (https=)
CA (1) CA3095415A1 (https=)
DK (1) DK3778573T3 (https=)
ES (1) ES2980254T3 (https=)
FI (1) FI3778573T3 (https=)
HR (1) HRP20240788T1 (https=)
HU (1) HUE066972T2 (https=)
MX (1) MX2020009967A (https=)
PL (1) PL3778573T3 (https=)
PT (1) PT3778573T (https=)
RS (1) RS65692B1 (https=)
SG (1) SG11202009088VA (https=)
SI (1) SI3778573T1 (https=)
TW (1) TWI825085B (https=)
WO (1) WO2019189778A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity
CN120623106A (zh) * 2019-09-30 2025-09-12 协和麒麟株式会社 Bet降解剂
CN110693864B (zh) * 2019-10-31 2022-08-26 重庆医科大学 一类三羰基化合物在制备抗人宫颈癌药物中的应用
JP7419406B2 (ja) * 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
JP7614145B2 (ja) * 2021-08-05 2025-01-15 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導剤を含む医薬
WO2025127150A1 (ja) * 2023-12-15 2025-06-19 協和キリン株式会社 ２価ｂｅｔ分解薬およびターゲティング分子－薬物複合体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849458A (en) 1966-01-21 1974-11-19 Incentive Res & Dev Ab Method for deuterating organic compounds
JPS61148141A (ja) 1984-12-21 1986-07-05 Mitsubishi Rayon Co Ltd 重水素化アクリル酸メチルまたは重水素化メタクリル酸メチルの製造法
JPS61275241A (ja) 1985-05-29 1986-12-05 Mitsubishi Rayon Co Ltd 重水素化アクリル酸又は重水素化メタクリル酸の製造方法
JPS61277648A (ja) 1985-06-03 1986-12-08 Mitsubishi Rayon Co Ltd 重水素化アクリル酸又は重水素化メタクリル酸の製造方法
DE3701302A1 (de) 1987-01-17 1988-07-28 Hoechst Ag Verfahren zur herstellung von deuterierten organischen verbindungen
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
HUE043568T2 (hu) 2013-03-14 2019-08-28 Glaxosmithkline Ip No 2 Ltd 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
WO2015081284A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MX2018006499A (es) * 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2018111805A1 (en) 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity

Similar Documents

Publication Publication Date Title
JPWO2019189778A5 (https=)
JP2022533398A5 (https=)
JP2023527891A5 (https=)
JPWO2022138987A5 (https=)
Solak et al. Synthesis and antituberculosis activity of 2-(aryl/alkylamino)-5-(4-aminophenyl)-1, 3, 4-thiadiazoles and their Schiff bases
PL402388A1 (pl) Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
JP2018517760A5 (https=)
NO20052626L (no) Middel for forhindring eller behandling av neuropati
MX2023006364A (es) Derivado de 5-heteroaril-1h-pirazol-3-amina.
JP2008510828A5 (https=)
JPWO2021065980A5 (https=)
FR2468593A1 (fr) Derives de 4-phenylphtalazine utilisables comme medicaments inhibiteurs de l'agregation de plaquettes sanguines, et procede pour leur preparation
JP2021522226A5 (https=)
JP2020537645A5 (https=)
EA200100708A1 (ru) 1, 2-аннелированные производные хинолина
PL169307B1 (pl) Sposób wytwarzania pochodnych triazolu PL PL PL PL PL
CA2578068A1 (en) S-triazolyl .alpha.-mercaptoacetanildes as inhibitors of hiv reverse transcriptase
JP2019512485A5 (https=)
TW200406383A (en) Method for preparing 3-halo-4,5-dihydro-1H-pyrazoles
JP2024521895A5 (https=)
JP2020521739A5 (https=)
JP2021522340A5 (https=)
JP2023538524A5 (https=)
RU2016129067A (ru) Азотсодержащие гетероциклические производные и их применение в лекарственных препаратах
JP2022533939A5 (https=)